Tag archive for ‘Small cell lung cancer’
By pharmanewsdaily On Sunday, January 31st, 2021
0 Comments

Amgen gets breakthrough therapy status for sotorasib in China

Amgen said that sotorasib, an investigational KRASG12C inhibitor, has been given breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) More...

By pharmanewsdaily On Wednesday, July 15th, 2020
0 Comments

Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib

Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 billion for the latter’s cancer drug More...

By pharmanewsdaily On Saturday, May 9th, 2020
0 Comments

Selpercatinib FDA approval : Lilly’s therapy approved for treatment of lung and thyroid cancers with RET alteration

Selpercatinib FDA approval : The US Food and Drug Administration (FDA) has approved Eli Lilly and Company’s Retevmo (selpercatinib) capsules for the treatment of three types of tumors – non-small cell lung More...

By pharmanewsdaily On Saturday, May 9th, 2020
0 Comments

Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers

Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Retevmo (selpercatinib, 40mg and 80mg capsules) for the treatment of adults with metastatic More...

Takeda Pharmaceutical Head Office in Tokyo
By pharmanewsdaily On Saturday, November 3rd, 2018
0 Comments

Pfizer lung cancer drug Lorbrena bags US FDA approval

Lorbrena FDA approval : US pharma giant Pfizer has bagged approval from the US Food and Drug Administration (FDA) for Lorbrena (lorlatinib) for anaplastic lymphoma kinase (ALK) positive metastatic non-small cell More...

By pharmanewsdaily On Monday, October 15th, 2018
0 Comments

BMS’ Opdivo flops in CheckMate -331 trial in small cell lung cancer

Bristol-Myers Squibb (BMS) cancer drug Opdivo (nivolumab) failed to meet the primary endpoint of the phase 3 CheckMate -331 trial in small cell lung cancer patients whose condition relapsed after platinum-based More...

By pharmanewsdaily On Sunday, August 5th, 2018
0 Comments

PharmaMar lung cancer drug lurbinectedin gets FDA orphan drug designation

Spanish pharma company PharmaMar’s lurbinectedin has secured orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of small cell lung cancer. Lurbinectedin has been designed More...